Last Updated: 15 Sep 2024
Executive Summary
Veracyte Inc. (VCYT) is a genomic diagnostics company with a market capitalization of $2.53 billion. The company has been reporting negative earnings per share (-$0.74) and a profit margin of -0.135%. However, it has experienced a 0.267% growth in quarterly revenue year-over-year. Analysts have a consensus rating of "Buy" with a target price of $34.57, indicating potential for upside.
Company Overview
Veracyte is headquartered in South San Francisco, California and specializes in genomic diagnostics. Its mission is to improve the lives of patients by providing actionable information through genomic testing. The company's portfolio includes tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.
Fundamental Analysis
Revenue: $399.58 million TTM
Gross Profit: $194.95 million TTM
Operating Margin: 4.72% TTM
Return on Assets: 0.38% TTM
Return on Equity: -4.88% TTM
Veracyte's revenue has grown steadily, but its profitability remains a concern. The company's negative earnings per share and low profit margin indicate that it is not yet generating sufficient revenue to cover its expenses.
Technical Analysis
52-Week High: $33.33
52-Week Low: $18.61
50-Day Moving Average: $27.24
200-Day Moving Average: $24.29
Beta: 1.662
The stock price of VCYT has been volatile over the past year, but it has generally trended upwards. The current price of $32.92 is above both the 50-day and 200-day moving averages, indicating a bullish trend.
Short Term Outlook
In the short term, Veracyte is expected to continue to face challenges in terms of profitability. However, the company's strong revenue growth and positive analyst sentiment suggest that it may be able to turn a profit in the future.
Long Term Outlook
The long-term outlook for Veracyte is positive. The company's genomic testing platform has the potential to revolutionize the way that diseases are diagnosed and treated. If Veracyte can successfully commercialize its tests and expand its market share, it could become a major player in the healthcare industry.
Analyst Recommendations
Analysts have a consensus rating of "Buy" for Veracyte, with a target price of $34.57. This indicates that analysts believe that the stock is undervalued and has the potential for upside.
